Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -226.15% | -56.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -226.15% | -56.52% | |||
| Cost of Revenue | -118.71% | 635.48% | |||
| Gross Profit | 93.49% | -369.76% | |||
| SG&A Expenses | -71.82% | -29.83% | |||
| Depreciation & Amortization | -46.78% | 18.18% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -72.61% | -3.43% | |||
| Operating Income | 67.92% | -0.28% | |||
| Income Before Tax | 59.99% | -110.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 59.99% | -110.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.99% | -110.69% | |||
| EBIT | 67.92% | -0.28% | |||
| EBITDA | 76.94% | 5.81% | |||
| EPS Basic | 59.90% | -111.83% | |||
| Normalized Basic EPS | 92.68% | -112.07% | |||
| EPS Diluted | 59.90% | -111.83% | |||
| Normalized Diluted EPS | 92.68% | -112.07% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||